Pan-cancer pervasive upregulation of 3′ UTR splicing drives tumourigenesis
-
Published:2022-05-26
Issue:6
Volume:24
Page:928-939
-
ISSN:1465-7392
-
Container-title:Nature Cell Biology
-
language:en
-
Short-container-title:Nat Cell Biol
Author:
Chan Jia Jia, Zhang Bin, Chew Xiao Hong, Salhi Adil, Kwok Zhi Hao, Lim Chun You, Desi Ng, Subramaniam Nagavidya, Siemens Angela, Kinanti Tyas, Ong Shane, Sanchez-Mejias Avencia, Ly Phuong Thao, An Omer, Sundar Raghav, Fan Xiaonan, Wang Shi, Siew Bei En, Lee Kuok Chung, Chong Choon Seng, Lieske Bettina, Cheong Wai-Kit, Goh Yufen, Fam Wee Nih, Ooi Melissa G., Koh Bryan T. H., Iyer Shridhar Ganpathi, Ling Wen Huan, Chen Jianbin, Yoong Boon-Koon, Chanwat Rawisak, Bonney Glenn Kunnath, Goh Brian K. P., Zhai Weiwei, Fullwood Melissa J., Wang Wilson, Tan Ker-Kan, Chng Wee Joo, Dan Yock Young, Pitt Jason J., Roca Xavier, Guccione Ernesto, Vardy Leah A., Chen Leilei, Gao Xin, Chow Pierce K. H., Yang Henry, Tay YvonneORCID
Abstract
AbstractMost mammalian genes generate messenger RNAs with variable untranslated regions (UTRs) that are important post-transcriptional regulators. In cancer, shortening at 3′ UTR ends via alternative polyadenylation can activate oncogenes. However, internal 3′ UTR splicing remains poorly understood as splicing studies have traditionally focused on protein-coding alterations. Here we systematically map the pan-cancer landscape of 3′ UTR splicing and present this in SpUR (http://www.cbrc.kaust.edu.sa/spur/home/). 3′ UTR splicing is widespread, upregulated in cancers, correlated with poor prognosis and more prevalent in oncogenes. We show that antisense oligonucleotide-mediated inhibition of 3′ UTR splicing efficiently reduces oncogene expression and impedes tumour progression. Notably, CTNNB1 3′ UTR splicing is the most consistently dysregulated event across cancers. We validate its upregulation in hepatocellular carcinoma and colon adenocarcinoma, and show that the spliced 3′ UTR variant is the predominant contributor to its oncogenic functions. Overall, our study highlights the importance of 3′ UTR splicing in cancer and may launch new avenues for RNA-based anti-cancer therapeutics.
Funder
King Abdullah University of Science and Technology Ministry of Education - Singapore MOH | National Medical Research Council
Publisher
Springer Science and Business Media LLC
Reference47 articles.
1. Mayr, C. What are 3’ UTRs doing? Cold Spring Harb. Perspect. Biol. 11, a034728 (2018). 2. Kataoka, K. et al. Aberrant PD-L1 expression through 3′-UTR disruption in multiple cancers. Nature 534, 402–406 (2016). 3. Schuster, S. L. & Hsieh, A. C. The untranslated regions of mRNAs in cancer. Trends Cancer 5, 245–262 (2019). 4. Mayr, C. & Bartel, D. P. Widespread shortening of 3′ UTRs by alternative cleavage and polyadenylation activates oncogenes in cancer cells. Cell 138, 673–684 (2009). 5. Lianoglou, S., Garg, V., Yang, J. L., Leslie, C. S. & Mayr, C. Ubiquitously transcribed genes use alternative polyadenylation to achieve tissue-specific expression. Genes Dev. 27, 2380–2396 (2013).
Cited by
27 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|